Close Menu

    Subscribe to Updates

    Get the latest creative news from FooBar about art, design and business.

    What's Hot

    Botswana reviews proposed 33% power tariff hike today

    November 19, 2026

    MITHRA Metals Highlights Its Role in Bridging the GCC Mining Investment Gap at The Mining Show 2026

    November 19, 2026

    PM Modi meets Prince and Princess of Wales in New Delhi

    November 19, 2026
    Facebook X (Twitter) Instagram
    Iraq HeraldIraq Herald
    • Automotive
    • Business
    • Entertainment
    • Health
    • Lifestyle
    • Luxury
    • News
    • More
      • Sports
      • Technology
      • Travel
    Iraq HeraldIraq Herald
    Home » Peptomyc Announces the Approval of Its Phase 1b Trial Testing OMO-103 in Combination With Standard of Care in PDAC Patients
    ACCESS Newswire

    Peptomyc Announces the Approval of Its Phase 1b Trial Testing OMO-103 in Combination With Standard of Care in PDAC Patients

    July 28, 20233 Mins Read

    OMO-103 in Phase 1b clinical trial

    BARCELONA, SPAIN / ACCESSWIRE / July 27, 2023 / Peptomyc S.L., a biotech company specialized in the development of protein therapeutics for cancer treatment, announces that it has received full study approval for its new Phase 1b clinical trial, which will evaluate the combination of the first-in-class MYC inhibitor, OMO103, together with the standard of care (SoC) regimen Gemcitabine and Nab-Paclitaxel in metastatic Pancreatic Ductal Adenocarcinoma (PDAC) patients in first line. PDAC is the most common form of pancreatic cancer. Currently, it is the fourth highest cause of cancer mortality worldwide and its incidence is rising steeply. Current therapies offer limited chance of a lasting cure and the five-year survival rate is one of the lowest among the most commonly occurring cancers.

    Peptomyc logo
    Peptomyc logo
    Peptomyc logo

    MYC is an oncoprotein deregulated in most -if not all- types of cancers. It is activated in many PDAC cases, where it contributes to aggressiveness of the disease and resistance to treatments. The company recently completed a FIH Phase 1 study of OMO103 in all-comers solid tumor patients, demonstrating excellent safety and promising anti-tumor activity.

    Manuela Niewel, MD, PhD, Chief Medical Officer of the company, leading Peptomyc’s clinical development, regulatory and medical affairs activities, says: “I am excited to be able to start our new Phase 1b study in PDAC patients. With OMO-103, we hope to address this devastating disease and one of the highest unmet medical needs in the oncology field”.

    This Phase 1b combination study will be conducted in four sites in Spain. The lead PI will be Dr. Teresa Macarulla at the Vall d’Hebron Institute of Oncology in Barcelona, and she will collaborate with Dr. Andres Muñoz at the Hospital Gregorio Marañon in Madrid, Dr. Mariona Calvo at the ICO-Hospitalet in Barcelona, and Dr. Roberto Pazo at the Hospital Miguel Servet in Zaragoza. The study is planned to start in Q3/2023.

    About Peptomyc

    Peptomyc (www.peptomyc.com) is a spin-off from VHIO – the Vall d’Hebron Institute of Oncology – and ICREA – the Catalan Institute of Research and Advanced Studies – founded in December 2014 in Barcelona, Spain. The company is focused on the development of innovative cell penetrating peptides (CPPs) targeting the Myc oncoprotein for cancer treatment and based on Dr. Soucek’s scientific research in Omomyc (the best direct Myc inhibitor known to date) over the last twenty years. It is the first company to have successfully completed a Phase I clinical trial with a direct MYC inhibitor.

    Contact Information

    Laura Soucek
    CEO
    lsoucek@peptomyc.com
    +34695207869

    SOURCE: Peptomyc SL

    .
    Share. Facebook Twitter Pinterest LinkedIn Telegram Reddit Email

    Related Posts

    Freezz Italia Awarded ESA Contract for IRIS(2) Low-LEO Pre-Operational and De-Risk Activities

    November 17, 2026

    Chervon Names Doug Palmer Vice President of Finance – Canada

    November 5, 2026

    Chervon Promotes Soobia Haroon to Vice President, Human Resources – NA

    November 2, 2026

    Miami Fashion Week(R) Celebrates 10 Years With a Landmark Anniversary Edition, October 13-18, 2026

    October 26, 2026

    Chervon Names Maggie Jones Director of National Field Sales OPS

    October 26, 2026

    GA-ASI Partnering With Spirit Defense For FQ-42 CCA Production

    October 23, 2026
    Editor's Pick

    Botswana reviews proposed 33% power tariff hike today

    November 19, 2026

    The state energy regulator has officially initiated a comprehensive public review process regarding a substantial electricity rate increase requested by the national utility provider. Confirming the scope of this critical regulatory review, Botswana opens consultations on proposed 33 percent power

    PM Modi meets Prince and Princess of Wales in New Delhi

    November 19, 2026

    Petrol price jump lifts South Africa inflation as SARB weighs rates

    November 18, 2026

    Congo Ebola death toll reaches 5,568 as cases pass 11,000

    November 18, 2026

    DXB handles 50.4 million passengers in first nine months

    November 18, 2026

    ASEAN signs digital economy pact eyeing $2 trillion by 2030

    November 18, 2026
    © 2026 Iraq Herald | All Rights Reserved
    • Home
    • Contact Us

    Type above and press Enter to search. Press Esc to cancel.